Vol. 21/No. 19 | Oncology Live®

October 09, 2020

An increased understanding of the biologic intricacies of acute myeloid leukemia has led to the identification of more than 100 driver mutations associated with the disease, opening the door for targeted therapies with clinically meaningful outcomes for patients who are not candidates for intensive chemo-therapy regimens.

October 09, 2020

Palliative medicine has evolved to become a standard for high-quality cancer care, helping patients relieve suffering throughout their journey, improving quality of life, and prolonging survivorship.

October 08, 2020

Maintaining sexual function is often low on the list of priorities for a woman recently diagnosed with a gynecologic cancer, but raising the subject early in her treatment course may make the patient more willing to engage in a discussion as her care progresses.

October 08, 2020

Investigators are developing a new way to target a key oncogenic mechanism that may prove to be an effective anticancer strategy, particularly against hematologic malignancies.

October 07, 2020

In recent years, great progress has been made in understanding the genetics of metastatic prostate cancer which has translated into the development of new precision therapies.

October 07, 2020

The addition of the experimental small molecule eprenetapopt to a standard treatment for myelodysplastic syndromes is showing promise in patients with TP53 mutations.

October 06, 2020

Patients with cancer continue to find their health care providers “more helpful” in managing physical adverse effects resulting from cancer therapy compared with emotional or mental health AEs.

October 06, 2020

The 2020 class of Giants of Cancer Care® award winners hail from around the globe, coming from locales such as Lagos, Nigeria; Amsterdam, the Netherlands; Brussels, Belgium; and Philadelphia, Pennsylvania.

October 05, 2020

Findings have shown that patients with cancer are at an increased risk of developing severe illness due to coronavirus disease 2019.

October 01, 2020

In an interview with OncologyLive®, Justin F. Gainor, MD, discusses the impact pralsetinib may have on the RET-altered NSCLC paradigm.

September 30, 2020

In the realm of medicine, we see enormous opportunities for truly novel technologies to revolutionize the health and welfare of all members of society.